VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 1 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2023. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $7,536,000 | +21.9% | 306,966 | 0.0% | 0.74% | +12.9% |
| Q2 2016 | $6,182,000 | -23.8% | 306,966 | -0.6% | 0.65% | -19.4% |
| Q1 2016 | $8,118,000 | -93.0% | 308,666 | -72.8% | 0.81% | -90.6% |
| Q4 2015 | $115,530,000 | -53.0% | 1,136,554 | -17.5% | 8.56% | -36.6% |
| Q3 2015 | $245,827,000 | -18.7% | 1,378,108 | +1.3% | 13.50% | -12.2% |
| Q2 2015 | $302,291,000 | +69.5% | 1,360,752 | +51.5% | 15.37% | +39.2% |
| Q1 2015 | $178,356,000 | +40.0% | 897,976 | +0.8% | 11.04% | +22.4% |
| Q4 2014 | $127,429,000 | -2.5% | 890,426 | 0.0% | 9.02% | -6.6% |
| Q3 2014 | $130,670,000 | +20.2% | 890,426 | +3.3% | 9.66% | +7.7% |
| Q2 2014 | $108,745,000 | +8.0% | 862,236 | +24.4% | 8.97% | +10.8% |
| Q1 2014 | $100,703,000 | +23.7% | 693,381 | 0.0% | 8.09% | +16.0% |
| Q4 2013 | $81,403,000 | +15.0% | 693,381 | +2.2% | 6.98% | -7.3% |
| Q3 2013 | $70,811,000 | +112.9% | 678,719 | +75.7% | 7.53% | +84.2% |
| Q2 2013 | $33,253,000 | – | 386,300 | – | 4.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |